Induced pluripotent stem-cell-derived corneal epithelium to treat limbal stem cell deficiency could transform eye care and restore human vision, new evidence has revealed.
Limbal stem cell deficiency (LSCD) is characterised by a loss or deficiency of the stem cells in the limbus that are vital for the re-population of the corneal epithelium and to the barrier function of the limbus.
Experts have highlighted that the loss of functioning adult stem cells at the cornea’s edge can trigger vision impairment because of the invasion of fibrotic conjunctival tissue over the cornea.
- Human cells grown in artificial eye could transform lives of people with macular degeneration
- Eye health: why diabetes impact eye healing
- Colourful fruit and vegetables boost eye and brain health
Traditionally, limbal stem cells perform repair functions by differentiating into corneal epithelium.
The integrity and transparency of the corneal surface becomes compromised without limbal stem cells and can cause a buildup of fibrotic tissue and potentially vision loss.
Grafts from the patient’s healthy eye or a donor’s eye is a traditional treatment method but these can cause an immunological rejection.
During the trial, the team of academics from Osaka University in Japan tried treating LSCD by carrying out transplants of pluripotent stem cell (iPSC)-derived corneal epithelial sheets (iCEPS).
A total of four people took part in the study, all of whom had LSCD. Each participant underwent a procedure where transplanted allogeneic iCEPS were put onto the affected eyes.
Approximately 50% of the participants received low-dose cyclosporine and the other half received no immunosuppressive agents beyond corticosteroids.
- Eye stroke: Link between semaglutide and eye condition identified
- Rare eye condition can be triggered by weight loss jab
- AI-powered eye exams improve screening rates among young people with diabetes
The research team observed the participants for two years. They reported no severe adverse events, and any minor adverse events were managed effectively and without lasting effects.
Substantial improvements to vision were seen by all the participants, and three out of the four partakers experienced an improved quality-of-life.
Health outcomes were better among the participants who received low-dose cyclosporine, the study has reported.
Read the study in The Lancet.
